We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+16.34%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.59B
AUM Growth
+$94.4M
(+3.8%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-5.13%
Top 10 Holdings %
Top 10 Hldgs %
44.17%
Holding
70
New
30
Increased
7
Reduced
17
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maravai LifeSciences
MRVI
|
+$87.3M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$79.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$72.1M |
| 4 |
HOLX
Hologic
HOLX
|
+$71.8M |
| 5 |
McKesson
MCK
|
+$70.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$113M |
| 2 |
Zimmer Biomet
ZBH
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$107M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$93.1M |
| 5 |
Medtronic
MDT
|
+$87.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.87% |
| 2 | Real Estate | 3.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Envista
NVST
$4.52B
| $35.1M | 1.35% |
+1,039,290
| New | +$30.1M |
|
27
Ventas
VTR
$47.9B
| $32.3M | 1.25% |
+658,350
| New | +$30.4M |
|
28
Edwards Lifesciences
EW
$51.7B
| $29.3M | 1.13% |
321,200
+97,340
| +43% | +$8.07M |
|
|
HZNP
29
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $29.3M | 1.13% |
+400,000
| New | +$29.7M |
|
|
CTLT
30
DELISTED
CATALENT, INC.
CTLT
| $28.1M | 1.08% |
+270,250
| New | +$26.2M |
|
31
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$823B
| $28M | 1.08% |
+75,000
| New | +$26.6M |
|
32
Omega Healthcare
OHI
$14.7B
| $28M | 1.08% |
+770,910
| New | +$26.1M |
|
|
NVRO
33
DELISTED
NEVRO CORP.
NVRO
| $27M | 1.04% |
156,046
-574,931
| -79% | -$93.1M |
|
34
Charles River Laboratories
CRL
$12.8B
| $26.9M | 1.04% |
107,800
-134,430
| -55% | -$32M |
|
35
Syndax Pharmaceuticals
SNDX
$1.82B
| $23.8M | 0.92% |
1,070,550
+1,038,350
| +3,225% | +$21.5M |
|
36
Welltower
WELL
$171B
| $23.1M | 0.89% |
+357,120
| New | +$21.7M |
|
37
Neurocrine Biosciences
NBIX
$16.6B
| $21.7M | 0.84% |
226,460
-700,610
| -76% | -$67.7M |
|
38
PUT
iShares Russell 2000 ETF
IWM
$83B
| $20.6M | 0.79% |
+105,000
| New | +$18.4M |
|
39
BioMarin Pharmaceuticals
BMRN
$12.3B
| $19.5M | 0.75% |
222,210
+207,610
| +1,422% | +$16.5M |
|
40
Curis
CRIS
$7.83M
| $19.4M | 0.75% |
+5,936
| New | +$7.13M |
|
41
Tenet Healthcare
THC
$21.1B
| $17.2M | 0.66% |
431,441
-683,539
| -61% | -$22.1M |
|
42
CONMED
CNMD
$1.47B
| $11.2M | 0.43% |
+100,000
| New | +$9.47M |
|
|
ALXN
43
DELISTED
Alexion Pharmaceuticals
ALXN
| $9.58M | 0.37% |
+61,330
| New | +$7.88M |
|
|
DCPH
44
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $7.95M | 0.31% |
+139,210
| New | +$8.25M |
|
|
FOLD
45
PUT
DELISTED
Amicus Therapeutics
FOLD
| $5.77M | 0.22% |
+250,000
| New | +$5.11M |
|
46
Teleflex
TFX
$5.98B
| $5.41M | 0.21% |
13,150
-152,010
| -92% | -$56.1M |
|
47
Certara
CERT
$1.25B
| $5.06M | 0.2% |
+150,000
| New | +$5.49M |
|
48
Biogen
BIIB
$30.7B
| $2.34M | 0.09% |
+9,560
| New | +$2.47M |
|
|
AMRN
49
Amarin Corp
AMRN
$303M
| $1.92M | 0.07% |
+19,638
| New | +$1.89M |
|
50
Cigna
CI
$74.6B
| $1.77M | 0.07% |
+8,502
| New | +$1.67M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2020 Portfolio in Review
As of Q4 2020, HealthCor Management held 70 positions worth $2.59B, up 3.8% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
HealthCor Management withdrew a net $133M in Q4 2020, closing 16 positions and reducing 17 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $107M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier, followed by Real Estate.
Against the trend, HealthCor Management opened a new position in Maravai LifeSciences worth $87.9M.
- HealthCor Management's largest Q4 2020 buy was Maravai LifeSciences: 3,134,712 shares worth $87.9M.
- HealthCor Management added most to Bristol-Myers Squibb in Q4 2020, an estimated $72.1M increase.
- HealthCor Management's biggest Q4 2020 reduction was UnitedHealth, cutting an estimated $113M.
- HealthCor Management fully exited Regeneron Pharmaceuticals in Q4 2020, selling an estimated $107M.
- HealthCor Management's ten largest holdings make up 44% of its $2.59B portfolio in Q4 2020.
- HealthCor Management opened 30 new positions and closed 16 in Q4 2020.
- HealthCor Management's portfolio value rose 3.8% quarter-over-quarter to $2.59B.
Based on HealthCor Management's 13F filing for Q4 2020, filed 16 Feb 2021.